John Barkett, MBA

Managing director in Berkeley Research Group's Healthcare Transactions and Strategy practice

Articles

May 26th 2025

Congress Unlikely to Codify Executive Order on Drug Pricing: John Barkett, MBA

Congress is unlikely to codify the recent executive order to lower drug pricing as other US officials negotiate new prices, John Barkett, MBA, of Berkeley Research Group, explains.

May 23rd 2025

Effects of Executive Order Could Take Years to Appear: John Barkett, MBA

Julia Bonavitacola John Barkett, MBA

The immediate impact of the recent executive order aimed at lowering drug prices is likely low, as it may take until 2027 before actions detailed in the order can be enacted.

May 21st 2025

Legal Challenges Likely Following Drug Pricing Executive Order: John Barkett, MBA

Julia Bonavitacola John Barkett, MBA

The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.

May 19th 2025

How Trump's New Drug Pricing EO Differs From Past Attempts: John Barkett, MBA

Julia Bonavitacola John Barkett, MBA

The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.

May 16th 2025

New Executive Order Aims for Most-Favored Nation Pricing: John Barkett, MBA

Julia Bonavitacola John Barkett, MBA

The new executive order contains multiple provisions if pharmaceutical companies do not offer "most-favored nation" pricing on medication.